Dr. Redfern is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3075 Health Center Dr
Suite 102
San Diego, CA 92123Phone+1 858-637-7888Fax+1 858-637-7887
Education & Training
- University of California (San Francisco)/FresnoFellowship, Hematology and Medical Oncology, 1994 - 1996
- Johns Hopkins UniversityResidency, Internal Medicine, 1991 - 1994
- Johns Hopkins University School of MedicineClass of 1991
Certifications & Licensure
- CA State Medical License 1994 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013
Clinical Trials
- Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients Start of enrollment: 2004 Mar 01
Publications & Presentations
PubMed
- 3930 citationsSipuleucel-T immunotherapy for castration-resistant prostate cancer.Philip W. Kantoff, Celestia S. Higano, N. Shore, E. Roy Berger, Eric J. Small
The New England Journal of Medicine. 2010-07-23 - 58 citationsPilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancerPeter D. Boasberg, Charles H. Redfern, Gregory A. Daniels, David Bodkin, Christopher R. Garrett
Cancer Chemotherapy and Pharmacology. 2011-04-24 - 274 citationsOlaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.Noel W. Clarke, Paweł Wiechno, Boris Alekseev, Nuria Sala, Robert H. Jones
The Lancet. Oncology. 2018-07-01
Press Mentions
- Why Did Carter and McCain Have Such Different Brain Tumor Results?August 26th, 2018
Grant Support
- G Protein Signaling And Tissue ProliferationNational Cancer Institute1996–1998
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: